Skip to Content
Merck
CN

V000590

2-Mercaptoethanol

99.0%

Synonym(s):

β-Mercaptoethanol, 2-Hydroxyethylmercaptan, BME, Thioethylene glycol

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Linear Formula:
HSCH2CH2OH
CAS Number:
60-24-2
Molecular Weight:
78.13
EC Number:
200-464-6
PubChem Substance ID:
329828106
MDL number:
MFCD00004890
Beilstein/REAXYS Number:
773648

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

DGVVWUTYPXICAM-UHFFFAOYSA-N

InChI

1S/C2H6OS/c3-1-2-4/h3-4H,1-2H2

SMILES string

OCCS

grade

synthesis grade

vapor density

2.69 (vs air)

vapor pressure

1 mmHg ( 20 °C)

assay

99.0%

expl. lim.

18 %

concentration

14.3 M (pure liquid)

Quality Level

100

bp

157 °C (lit.)

density

1.114 g/mL at 25 °C (lit.)

Looking for similar products? Visit Product Comparison Guide

Application

BME is suitable for reducing protein disulfide bonds prior to polyacrylamide gel electrophoresis and is usually included in a sample buffer for SDS-PAGE at a concentration of 5%. Cleaving intermolecular (between subunits) disulfide bonds allows the subunits of a protein to separate independently on SDS-PAGE. Cleaving intramolecular (within subunit) disulfide bonds allows the subunits to become completely denatured so that each peptide migrates according to its chain length with no influence due to secondary structure.

signalword

Danger

Hazard Classifications

Acute Tox. 2 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 2 - Eye Dam. 1 - Repr. 2 - Skin Irrit. 2 - Skin Sens. 1A - STOT RE 2 Oral

target_organs

Liver,Heart

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

165.2 °F - closed cup

flash_point_c

74 °C - closed cup

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
DCBD6886V
DCBD6779V
DCBD6253V
DCBD5917V
DCBD4655V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Katharina Rothe et al.
Blood, 123(23), 3622-3634 (2014-04-24)
Previous studies demonstrated that imatinib mesylate (IM) induces autophagy in chronic myeloid leukemia (CML) and that this process is critical to cell survival upon therapy. However, it is not known if the autophagic process differs at basal levels between CML
Leon Tribolet et al.
The Journal of infectious diseases, 211(3), 416-425 (2014-08-21)
Na-ASP-2 is an efficacious hookworm vaccine antigen. However, despite elucidation of its crystal structure and studies addressing its immunobiology, the function of Na-ASP-2 has remained elusive. We probed a 9000-protein human proteome microarray with Na-ASP-2 and showed binding to CD79A
D Zhu et al.
Leukemia, 29(7), 1587-1599 (2015-02-14)
The pathogenesis of Chlamydophila psittaci-negative ocular adnexal extranodal marginal zone lymphomas (OAEMZLs) is poorly understood. OAEMZLs are monoclonal tumors expressing a biased repertoire of mutated surface immunoglobulins. Antigenic activation of the B-cell receptor (BCR) may have a role in the
Philipp Müller et al.
Cancer immunology research, 2(8), 741-755 (2014-06-12)
Antibody-drug conjugates (ADC) are emerging as powerful treatment strategies with outstanding target-specificity and high therapeutic activity in patients with cancer. Brentuximab vedotin represents a first-in-class ADC directed against CD30(+) malignancies. We hypothesized that its sustained clinical responses could be related
Philipp Müller et al.
Science translational medicine, 7(315), 315ra188-315ra188 (2015-11-27)
Targeted drug delivery with antibody-drug conjugates such as the HER2-directed ado-trastuzumab emtansine (T-DM1) has emerged as a powerful strategy for cancer therapy. We show that T-DM1 is particularly effective in eliciting antitumor immunity in patients with early breast cancer (WSG-ADAPT
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service